ClinicalTrials.gg
CompletedNCT02596217Updated Jul 6, 2017

Safety, Tolerability and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Healthy Asian and Caucasian Male Volunteers

A Phase 1 interventional study of ABBV-066 and ABBV-066 in Healthy, sponsored by AbbVie. Completed at 2 sites in 2 countries. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-06.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Male
01

Study summary

Safety, tolerability and pharmacokinetics of single dose of BI 655066/ABBV-066 (risankizumab) in healthy Chinese, Japanese and Caucasian male volunteers.

02

Conditions studied

  • Healthy

Keywords

  • ABBV-066
  • BI 655066
  • risankizumab
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects according to the investigator¿s assessment, based on a complete medical history including a physical examination, vital signs (BP, PR), 12-lead , and clinical laboratory tests
  2. Chinese ethnicity, Japanese ethnicity, or Caucasian according to the following criteria:

    • Chinese; born in China or ethnic Chinese born outside of China, and a descendent of 4 ethnic Chinese grandparents who were all born in china
    • Japanese; born in Japan, have lived outside of Japan \<10 years, and have parents and grandparents who were all born in Japan
    • Caucasian
  3. Age of 20 to 45 years (incl.)
  4. of 18.5 to 25 kg/m2 (incl.) for Chinese and Japanese subjects, BMI of 18.5 to 29.9 kg/m2 (incl.) for Caucasian subjects.
  5. Signed and dated written prior to admission to the study in accordance with GCP and local legislation.
  6. Male subjects who agree to minimize the risk of female partners becoming pregnant by fulfilling any of the following criteria starting from at least 30 days before the first administration of trial medication and until 30 days after trial completion:

    • Use of adequate , e.g. any of the following methods plus condom: implants, combined oral or vaginal contraceptives, intrauterine device
    • Sexually abstinent
    • Vasectomised (vasectomy at least 1 year prior to enrolment)
    • Surgically sterilised (including hysterectomy)

Exclusion criteria

Exclusion criteria:

  1. Any finding in the medical examination (including BP, PR or ) is deviating from normal and judged as by the investigator
  2. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  3. Any evidence of a concomitant disease judged as clinically relevant by the investigator
  4. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  5. Surgery of the gastrointestinal tract that could interfere with kinetics of the trial medication (except appendectomy and simple hernia repair)
  6. Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
  7. History of relevant orthostatic hypotension, fainting spells, or blackouts
  8. Chronic or relevant acute infections including , viral hepatitis and (or) tuberculosis or evidence of tuberculosis infection as defined by a positive QuantiFERON TB-Gold (or T-SPOT) test. Subjects with a positive QuantiFERON TB-Gold (or T-SPOT) test may participate in the study if further work up (according to local practice/guidelines) establishes conclusively that the subject has no evidence of active tuberculosis. If presence of latent tuberculosis is established, then treatment must have been initiated and maintained according to local country guidelines.
  9. History of relevant allergy or (including allergy to the trial medication or its )
  10. Intake of biologic agents other than current study medication or drugs considered likely to interfere with the safe conduct of the study
  11. Intake of drugs with a long half-life (more than 24 h) within 30 days or less than 10 half-lives of the respective drug prior to administration of trial medication
  12. Within 10 days prior to administration of trial medication, use of drugs that might reasonably influence the results of the trial or that might prolong the /QTc interval
  13. Participation in another trial with an drug within 90 days or 5 half-lives (whichever is greater) prior to planned administration of trial medication
  14. Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)
  15. Inability to refrain from smoking on specified trial days
  16. Alcohol abuse (consumption of more than 30 g per day)
  17. Drug abuse or positive drug screening
  18. Blood donation of more than 100 mL within 30 days prior to administration of trial medication or intended donation during the trial
  19. Intention to perform excessive physical activities within one week prior to administration of trial medication or during the trial
  20. Inability to comply with dietary regimen of trial site
  21. A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are repeatedly greater than 450 ms) or any other relevant ECG finding at screening
  22. A history of additional risk factors for Torsades de Pointes (such as heart failure, hypokalemia, or family history of Long QT Syndrome)
  23. Have received any live bacterial or live viral vaccination in the 12 weeks prior to the date of screening. Subjects must agree not to receive a live bacterial or live viral vaccination during the study and up to 12 months after the last administration of study drug
  24. Have received Bacille Calmette-Guerin (BCG) vaccination in the 12 months prior to the date of screening. Subjects must agree not to receive BCG vaccination during the study and up to 12 months after the last administration of study drug
  25. Subject is assessed as unsuitable for inclusion by the investigator, for instance, because considered not able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Stage 1 (low dose SC)

    Low dose administered by subcutaneous (SC) injection

    Drug: ABBV-066

  • Experimental
    Stage 1 (medium dose SC)

    Medium dose administered by subcutaneous (SC) injection

    Drug: ABBV-066

  • Experimental
    Stage 1 (high dose SC)

    High dose administered by subcutaneous (SC) injection

    Drug: ABBV-066

  • Experimental
    Stage 2 (low dose IV)

    Low dose administered by intraveneous (IV) infusion

    Drug: ABBV-066

  • Experimental
    Stage 2 (medium dose IV)

    Medium dose administered by intraveneous (IV) infusion

    Drug: ABBV-066

  • Experimental
    Stage 2 (high dose IV)

    High dose administered by intraveneous (IV) infusion

    Drug: ABBV-066

  • Placebo comparator
    Placebo SC (Stage1)

    Placebo administered by subcutaneous (SC) injection

    Drug: Placebo

  • Placebo comparator
    Placebo IV (Stage2)

    Placebo administered by intraveneous (IV) infusion

    Drug: Placebo

Interventions

  • SC injection

    Also known as: BI 655066, risankizumab

  • IV infusion

    Also known as: BI 655066, risankizumab

  • DrugPlacebo

    SC injection (stage 1)

  • DrugPlacebo

    IV infusion (stage 2)

06

What researchers measure

Primary outcomes

  1. Percentage of subjects with drug-related adverse events

    Time frame: Up to 144 days after screening

Secondary outcomes

  1. Time from dosing to the maximum plasma concentration of the analyte in plasma (tmax)

    Time frame: Up to 144 days after randomization

  2. Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to time of the last quantifiable plasma concentration (AUC0-tz)

    Time frame: Up to 144 days after randomization

  3. Maximum measured plasma concentration of the analyte in plasma (Cmax)

    Time frame: Up to 144 days after randomization

  4. Terminal half-life of the analyte in plasma (t1/2)

    Time frame: Up to 144 days after randomization

  5. Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-infinity)

    Time frame: Up to 144 days after randomization

07

Study locations

2 sites
  • Boehringer Ingelheim Investigational Site
    Tokyo, Sumida-ku, Japan
  • Boehringer Ingelheim Investigational Site
    Busan, Korea, Republic of
08

References and documents

Publications

  • Thakre N, D'Cunha R, Goebel A, Liu W, Pang Y, Suleiman AA. Population Pharmacokinetics and Exposure-Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis. Rheumatol Ther. 2022 Dec;9(6):1587-1603. doi: 10.1007/s40744-022-00495-0. Epub 2022 Sep 30. PubMed 36178584 ↗
  • Suleiman AA, Minocha M, Khatri A, Pang Y, Othman AA. Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials. Clin Pharmacokinet. 2019 Oct;58(10):1309-1321. doi: 10.1007/s40262-019-00759-z. PubMed 31054118 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2015 to primary completion in Jun 2017, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2015
First posted
Nov 4, 2015
StartActual
Aug 2015
Primary completionActual
Jun 2017
CompletionActual
Jun 2017
Last update
Jul 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02596217
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Nov 4, 2015
Start date
Aug 2015
Primary completion
Jun 2017
Completion
Jun 2017
Last update
Jul 6, 2017

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion